Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 101kWORD 18k
28 November 2017
Question for written answer P-007310-17
to the Commission
Rule 130
David Martin (S&D)

 Subject:  Right to affordable medicines in EU-Mercosur Trade Negotiations
 Answer in writing 

The pharmaceutical-related ‘TRIPs plus’ provisions that the EU negotiates in its free trade agreements (FTAs) have an impact on access to affordable medicines by developing countries, and especially least developed countries (LDCs). The EU has so far managed to strike a delicate balance between, on the one hand, ensuring that access to medicines is not undermined, and on the other hand, ensuring that effective incentives to continue pharmaceutical research are maintained.

In the context of the Mercosur negotiations, it is still unclear how this balance will be struck. It should be noted that Brazil is one of the main producers of generic medicines among developing countries.

Can the Commission ensure that the provisions on patents and data exclusivity in the intellectual property rights (IPR) text of the EU-Mercosur FTA will not undermine the right to affordable medicines?

How have the concerns of Mercosur countries, and notably Brazil, been taken into account?

Legal notice